rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ABSI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Absci Corp. (ABSI) Gets Downgraded. Here’s How Much
      Nov 17Yahoo FinanceABSI
      Absci stock price target lowered to $14 by Guggenheim on model adjustments
      Nov 16Investing.comABSI
      Absci (ABSI) Advances ABS 201 Plans, Is The 43% Discount Justified?
      Nov 13Yahoo FinanceABSI
      Absci Corp (ABSI) Q3 2026 Earnings Call Highlights: ABS-201 Momentum Builds as Cash Runway ...
      Nov 12Yahoo FinanceABSI
      Absci Corporation Q3 2026 Earnings Call Summary
      Nov 12Yahoo FinanceABSI
      Absci Q3 Earnings Call Highlights
      Nov 12Yahoo FinanceABSI
      Earnings call transcript: Absci Q3 2026 revenue miss weighs on shares
      Nov 12Investing.comABSI
      Absci earnings beat, revenue fell short of estimates
      Nov 12Investing.comABSI
      Absci Q3 2026 Earnings Call Transcript
      Nov 12BenzingaABSI
      Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
      Nov 12Yahoo FinanceABSI
      Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
      Nov 12Yahoo FinanceABSI
      Cathie Wood’s ARK sells Absci stock, buys Prime Medicine
      Nov 12Investing.comABSIPRME
      Truist reiterates Buy on Absci stock ahead of hair growth data
      Nov 9Investing.comABSITFC
      Absci (ABSI) Stock Could Be Overvalued Given Its Book Value Gap
      Nov 6Yahoo FinanceABSI
      Does Positive Hair Loss Trial Data Change The Bull Case For Absci Stock?
      Oct 30Yahoo FinanceABSI
      Absci Corp stock hits 52-week high at 12.06 USD
      Oct 29Investing.comABSI
      Jefferies Initiates Absci at Buy With $14 Price Target
      Oct 29Yahoo FinanceABSI
      Jefferies initiates Absci stock with buy on hair loss drug potential
      Oct 29Investing.comABSI
      Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks Rally
      Oct 28Yahoo FinanceABSI
      Absci to Participate in Upcoming Investor Conferences
      Oct 27Yahoo FinanceABSI
      Is Absci (ABSI) Undervalued As Positive ABS 201 Phase 1 Data Lifts Optimism?
      Oct 24Yahoo FinanceABSI
      Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop
      Oct 16Yahoo FinanceABSI
      Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026

      VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time)

      Oct 13Yahoo FinanceABSI
      Absci (ABSI) Stock Dropped, So What Is Behind The Latest Attention?
      Oct 7Yahoo FinanceABSI
      Guggenheim reiterates Absci stock rating on endometriosis trial delay
      Sep 28Investing.comABSI
      Absci plans phase 2 trial of ABS-201 for endometriosis in 2027
      Sep 24Investing.comABSI
      Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027
      Sep 24Yahoo FinanceABSI
      Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

      Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center

      Sep 24Yahoo FinanceABSI
      Absci (ABSI) Stock Looks Expensive Against Its Book Value
      Sep 22Yahoo FinanceABSI
      Absci at Morgan Stanley healthcare conference: AI platform meets clinical test
      Sep 16Investing.comABSIMS
      Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic

      Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom. Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% since its February 2026 initial public offering, while Absci Corporation (NASDAQ:ABSI)’s stock has more than doubled so far in 2026. Switzerland’s […]

      Sep 12Yahoo FinanceABSI
      Analysts Are Bullish on These Healthcare Stocks: Agilent (A), AbSci (ABSI)

      Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailABSIPLSE
      Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up (NASDAQ:ABSI)
      Sep 9Seeking AlphaABSI
      Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)
      Sep 8Seeking AlphaABSI
      Absci to Participate in Upcoming Investor Conferences

      VANCOUVER, Wash. and NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment Conference (New York, NY) Fireside chat on Tuesday, September 15th at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time Morgan Stanley 24th Annual Gl

      Sep 1Yahoo FinanceABSI
      Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade

      Hair loss biotechs Veradermics, Absci, and Cosmo are drawing investor bets on a market untouched since the 1990s.

      Aug 31Yahoo FinanceABSI
      Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine | Fortune

      Pattern hair loss affects an estimated 50 million men and 30 million women in the US, but there have been no new approved drugs since the late 1990s.

      Aug 29FortuneABSI

      This is the newest page. Registered accounts read further back.